Related Experiment Videos

Octreotide diminishes luminal nutrient transport activity, which is reversed by epidermal growth factor

A S Seydel1, J H Miller, T P Sarac

  • 1Department of Surgery, University of Rochester Medical Center, New York 14642, USA.

American Journal of Surgery
|September 1, 1996
PubMed
Abstract

Insights

Octreotide (SMS) hinders small bowel adaptation by reducing nutrient transport. However, epidermal growth factor (EGF) can reverse this detrimental effect, potentially benefiting patients with short bowel syndrome (SBS).

Area of Science:

  • Gastroenterology
  • Physiology
  • Pharmacology

Background:

  • Octreotide (SMS), a somatostatin analogue, is used to manage short bowel syndrome (SBS) by reducing intestinal output.
  • SMS may impede small bowel adaptation by inhibiting trophic hormones like epidermal growth factor (EGF).

Purpose of the Study:

  • To investigate the effects of SMS and EGF on nutrient transport in a rabbit model of SBS.
  • To determine if EGF can counteract the negative impact of SMS on small bowel adaptation.

Main Methods:

  • Surgical jejunoileal resection was performed on New Zealand White rabbits.
  • Rabbits received subcutaneous infusions of saline or EGF and injections of saline or SMS.
  • Intestinal brush border membrane vesicles were isolated to measure nutrient transport.

Main Results:

  • SMS significantly reduced active nutrient transport by decreasing functional carriers in the brush border membrane.
  • Epidermal growth factor (EGF) coinfusion ameliorated the negative effects of SMS.
  • Combined EGF and SMS treatment led to a 26% upregulation in nutrient transport.

Conclusions:

  • Octreotide (SMS) has detrimental effects on small bowel adaptation in SBS.
  • Epidermal growth factor (EGF) can reverse the negative impact of SMS and may offer therapeutic benefits for SBS patients.

Related Concept Videos